Clinical Integration of Next Generation Sequencing in patient care: experts tackle three key policy areas

As techniques such as next generation sequencing, which determines the precise order of the nucleotides that make up DNA, are used in patient diagnosis and treatment, three critical policy areas remain ill-defined:

  • Regulation by the U.S. Food and Drug Administration and Center for Medicare and Medicaid Services.
  • Reimbursement policies for clinical utility and payment.
  • Intellectual property protections including the patenting of human genes and proprietary.

jlme_42-3-supp_cover_1A comprehensive analysis of these three key policy areas is on its way and the initial findings appear in a special issue for the Journal of Law, Medicine & Ethics, with the aim of developing a coordinated policy approach.

Dr. Maggie Curnutte, postdoctoral associate in the Center for Medical Ethics and Health Policy at the Baylor College of Medicine, is one of the authors of the special issue and reports on this on the Baylor College of Medicine blog.

You can also download free of charge the policy analysis on Clinical Integration of Next Generation Sequencing here.

Advertisements
This entry was posted in Bioeconomy, Genomics, Health Policy and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s